Sponsors / KURA
KURA

Kura Oncology, Inc.

Company identity checked against sources

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
6Trials in this database
1Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS MutationsNCT02383927KURAPhase 2Completed2020-12-14Actual
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard TherapyNCT02464228KURAPhase 2Completed2021-03-31Actual
Tipifarnib in Subjects With Myelodysplastic SyndromesNCT02779777KURAPhase 2Terminated2018-08-28Actual
Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid LeukemiaNCT02807272KURAPhase 2Completed2020-11-30Actual
Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to TherapyNCT03719690KURAPhase 2Completed2023-05-02Actual
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLNCT07007312KURAPhase 3Recruiting2031-11Estimated

Latest recorded trial changes